Srinivas Akkaraju bought $1.2M of Neurogene (NGNE)
Executed Nov 26 2024, disclosed Nov 27 2024, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Nov 27 2024), the stock returned -15.4% (delay-adjusted); from the execution session (Nov 26 2024), -7.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline; 1 filing reported both), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +35.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $11.9M of SRRK (287,970 sh across 4 lots, as filed), executed Oct 23.
Healthcare · Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→